Detalhe da pesquisa
1.
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.
Haematologica
; 109(1): 115-128, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199127
2.
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
Haematologica
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634126
3.
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Ann Hematol
; 103(2): 451-461, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38110588
4.
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Cancer
; 127(12): 2003-2014, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626197
5.
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica
; 106(12): 3079-3089, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33179471
6.
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Br J Haematol
; 201(6): 1239-1244, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37057357
7.
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Cancers (Basel)
; 15(2)2023 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36672386
8.
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.
Blood Cancer J
; 13(1): 77, 2023 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37173322
9.
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.
Front Oncol
; 12: 1054458, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36505804
10.
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Dis Markers
; 2022: 3132941, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36051360
11.
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
Leuk Res
; 115: 106821, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35286939
12.
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Blood Adv
; 6(4): 1278-1295, 2022 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794172
13.
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Cancers (Basel)
; 14(11)2022 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35681796
14.
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Leuk Lymphoma
; 62(11): 2727-2736, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34121593
15.
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Blood Adv
; 5(3): 760-770, 2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33560390
16.
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study.
Transplant Cell Ther
; 27(4): 311.e1-311.e10, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33836871
17.
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Sci Rep
; 11(1): 20745, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671057
18.
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia
; 35(6): 1571-1585, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077867
19.
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Leukemia
; 35(8): 2358-2370, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33526859
20.
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.
Haematologica
; 93(1): 67-74, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18166787